Bruce P. Connop
Direktor/Vorstandsmitglied bei IBEX TECHNOLOGIES
Profil
Bruce P.
Connop is an Independent Director at IBEX Technologies, Inc. since 2017.
He is also the Vice President-Preclinical Research & Development at Active Pass Pharmaceuticals, Inc. since 1999.
Previously, he worked as the VP-Non Clinical & Pharmaceutical Development at Transition Therapeutics, Inc. from 2006 to 2012.
Dr. Connop holds a doctorate degree from Queen's University.
Aktive Positionen von Bruce P. Connop
| Unternehmen | Position | Beginn |
|---|---|---|
| IBEX TECHNOLOGIES | Direktor/Vorstandsmitglied | 11.10.2017 |
Active Pass Pharmaceuticals, Inc.
 Active Pass Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Active Pass Pharmaceuticals, Inc. develops drugs for infectious diseases. It engages in the development of drugs that inhibit ABC transporters. The firm also provides portfolio of therapeutic programs, including age-related macular degeneration, travelers' diarrhea, and lipid disorders. The company was founded by Peter B Reiner in 1998 and is headquartered in Vancouver, Canada. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1999 |
Ehemalige bekannte Positionen von Bruce P. Connop
| Unternehmen | Position | Ende |
|---|---|---|
| TRANSITION THERAPEUTICS INC | Corporate Officer/Principal | - |
Ausbildung von Bruce P. Connop
| Queen's University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Active Pass Pharmaceuticals, Inc.
Active Pass Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Active Pass Pharmaceuticals, Inc. develops drugs for infectious diseases. It engages in the development of drugs that inhibit ABC transporters. The firm also provides portfolio of therapeutic programs, including age-related macular degeneration, travelers' diarrhea, and lipid disorders. The company was founded by Peter B Reiner in 1998 and is headquartered in Vancouver, Canada. | Health Technology |
Transition Therapeutics, Inc.
 Transition Therapeutics, Inc. Medical SpecialtiesHealth Technology Transition Therapeutics, Inc. develops novel therapeutics for disease indications. It operates through research and development of therapeutic agents segment. The firm's products include ELND005 for the treatment of alzheimer's disease, bipolar disorder and down syndrome. Its metabolic drug candidate is TT401 for treatment of type 2 diabetes and accompanying obesity. Transition Therapeutics was founded by Tony F. Cruz on July 6, 1998 and is headquartered in Toronto, Canada. | Health Technology |
IBEX Technologies, Inc.
 IBEX Technologies, Inc. Medical SpecialtiesHealth Technology IBEX Technologies, Inc. manufactures and markets enzymes for biomedical use. The firm also specializes in the custom aliquoting, filling, and lyophilization of enzymes in diagnostic disposables for medical devices. Its products include glycobiology enzymes from flavobacterium heparinum, collagen assays, collagen antibodies, and diamine oxidase liquid. The company was founded by Robert A. Heft on April 10, 1972 and is headquartered in Montréal, Canada. | Health Technology |
